Keep the patients you've earned.
Every result lives inside your practice, tied to your record of the patient — a retention tool against the national online retailers and big-box chains angling to pull your renewals away.
Centaris Health · For eye-care practices
Vision testing that extends your practice — not around it.
OculiRX is a screening-grade, provider-reviewed visual-acuity test your patients take at home. You review and sign every result, it stays scoped to your practice, and it lives between their comprehensive exams. A way to stay connected to your patients — never a way around you.
Isn't this the online eye exam the AOA fought?
No — and the difference is the entire point.
- Provider-supervised, not direct-to-consumer. A licensed eye-care professional reviews and signs every result. OculiRX issues nothing on its own.
- An acuity measurement, not a refraction. It measures visual acuity. It does not produce a prescription.
- Built for between comprehensive exams — never a replacement for one. For diagnosis, disease screening, contact-lens fitting, or anything urgent, your patient sees you, in person.
For your practice
A retention tool, not a workaround.
Know who to bring in.
Acuity readings between visits give you a simple, standardized signal for prioritizing follow-up — who needs to be seen now, and who’s stable.
Stay connected between annual exams.
A provider-reviewed touchpoint that keeps you in the loop on your patients' vision year-round, instead of going dark between comprehensive exams.
A modern front door for an independent practice.
Offer the at-home convenience patients expect from the chains — under your name, on your terms, with you signing off.
For patients
Taking the test at home
Your provider invites you to OculiRX. The test calibrates your screen, checks your viewing distance with your webcam, and measures each eye with standardized letters. Your provider reviews and signs the result. It's a screening-grade record between your in-office exams — not a diagnosis, not a new prescription, and not a substitute for a complete eye exam.
Join the waitlist →Questions
Straight answers.
- Is OculiRX FDA-cleared?
- OculiRX is a Class I, 510(k)-exempt visual-acuity test — the same device type as the FDA-cleared Visibly Digital Acuity Product. It is a screening-grade, provider-reviewed acuity test; a licensed eye-care professional reviews and signs every result.
- Does it give my patient a new glasses prescription?
- No. OculiRX measures visual acuity — it does not perform refraction or produce a prescription. You review and sign every result, and you make any clinical decision, where permitted by your state.
- Can it detect eye disease?
- No. OculiRX does not diagnose disease and is not a substitute for a comprehensive eye exam. For diagnosis, disease screening, contact-lens fitting, or emergencies, your patient sees you, in person.
- How accurate is it?
- OculiRX uses standardized optotypes (ETDRS / logMAR), per-session screen calibration, and continuous distance monitoring to capture a screening-grade measurement. A formal validation study is in progress; we do not publish accuracy figures until the data supports them.
- Is patient data private?
- Yes. Patient demographics are encrypted at rest (AES-256-GCM, with the encryption key held as a Cloudflare Worker secret), session video is encrypted before storage, every connection runs over TLS, every access is logged in an append-only audit trail, and every record stays scoped to your practice.
For eye-care practices
Bring OculiRX to your practice.
OculiRX is a provider-supervised, screening-grade acuity test under Centaris Health Inc. Your patients screen at home; you review and sign every result. We are talking to optometrists and ophthalmology practices about bringing it into their workflow.
Regulatory
Where the line sits.
Regulatory status. OculiRX is a Class I, 510(k)-exempt visual-acuity test — the same device type as the FDA-cleared Visibly Digital Acuity Product. Centaris Health Inc. registers and lists as a Class I device manufacturer and operates under FDA general controls, including complaint handling and adverse-event reporting. The 510(k) exemption is conditional on OculiRX remaining a screening-grade acuity measurement; it is not a refraction, diagnosis, or prescription device. A 513(g) classification request and an independent validation study are underway.